Cart
sales@molnova.com
I-37
CAS No. 2359690-13-2
I-37( Pyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-6-(1-methylcyclopropyl)-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]- )
Catalog No. M22551 CAS No. 2359690-13-2
I-37 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 272 | In Stock |
|
| 10MG | 408 | In Stock |
|
| 25MG | 735 | In Stock |
|
| 50MG | 1103 | In Stock |
|
| 100MG | 1654 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameI-37
-
NoteResearch use only, not for human use.
-
Brief DescriptionI-37 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
-
DescriptionI-37 is a novel benzylamino substituted pyridopyrimidinone as SOS1 inhibitor.
-
In Vitro——
-
In Vivo——
-
SynonymsPyrido[4,3-d]pyrimidin-7(6H)-one, 2-methyl-6-(1-methylcyclopropyl)-4-[[(1R)-1-[2-methyl-3-(trifluoromethyl)phenyl]ethyl]amino]-
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorSOS1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2359690-13-2
-
Formula Weight416.45
-
Molecular FormulaC22H23F3N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.RAMHARTER JUERGEN,et al.Novel benzylamino substituted pyridopyrimidinone and derivative as SOS1 inhibitor.TW 201938557 A
molnova catalog
related products
-
GSK2008607
GSK2008607 is a potent B-RafV600E inhibitor with anticancer activity and can be used to study breast, colorectal, melanoma, thyroid, and ovarian cancers.
-
SOS1-IN-15
SOS1-IN-15 is an orally active and potent SOS1 inhibitor with potential antitumor activity.SOS1-IN-15 is used in the study of colon cancer.
-
R18
Antagonist of 14.3.3 proteins (KD ≈80 nM). Competitively inhibits 14.3.3-ligand interactions without requiring phosphorylation. Blocks the ability of 14.3.3 to bind to target proteins such as Raf-1, Bad, ASK1 and exoenzyme S.
